Matches in SemOpenAlex for { <https://semopenalex.org/work/W2055175265> ?p ?o ?g. }
- W2055175265 endingPage "546" @default.
- W2055175265 startingPage "533" @default.
- W2055175265 abstract "Identification of cytotoxic T-lymphocyte antigen-4 (CTLA-4) as a key negative regulator of T-cell activity led to development of the fully human, monoclonal antibody ipilimumab to block CTLA-4 and potentiate antitumor T-cell responses. Animal studies first provided insight into the ability of an anti–CTLA-4 antibody to cause tumor regression, particularly in combination regimens. Early clinical studies defined ipilimumab pharmacokinetics and possibilities for combinability. Phase II trials of ipilimumab in advanced melanoma showed objective responses, but a greater number of patients had disease stabilization. In a phase III trial, ipilimumab was the first agent to demonstrate an improvement in overall survival in patients with previously treated, advanced melanoma. The adverse event profile associated with ipilimumab was primarily immune-related. Adverse events can be severe and life-threatening, but most were reversible using treatment guidelines. Ipilimumab monotherapy exhibits conventional and new patterns of activity in advanced melanoma, with a delayed separation of Kaplan-Meier survival curves. The observation of some new response patterns with ipilimumab, which are not captured by standard response criteria, led to novel criteria for the evaluation of immunotherapy in solid tumors. Overall, lessons from the development of ipilimumab contributed to a new clinical paradigm for cancer immunotherapy evolved by the Cancer Immunotherapy Consortium." @default.
- W2055175265 created "2016-06-24" @default.
- W2055175265 creator A5000470144 @default.
- W2055175265 creator A5004106939 @default.
- W2055175265 creator A5015135453 @default.
- W2055175265 creator A5036054479 @default.
- W2055175265 creator A5048698138 @default.
- W2055175265 creator A5050974773 @default.
- W2055175265 creator A5057372249 @default.
- W2055175265 creator A5063277345 @default.
- W2055175265 creator A5086481435 @default.
- W2055175265 date "2010-10-01" @default.
- W2055175265 modified "2023-10-16" @default.
- W2055175265 title "Development of Ipilimumab: Contribution to a New Paradigm for Cancer Immunotherapy" @default.
- W2055175265 cites W1483194800 @default.
- W2055175265 cites W1966483230 @default.
- W2055175265 cites W1967084952 @default.
- W2055175265 cites W1971962339 @default.
- W2055175265 cites W1981528932 @default.
- W2055175265 cites W1985124264 @default.
- W2055175265 cites W1987407561 @default.
- W2055175265 cites W2013043293 @default.
- W2055175265 cites W2015085911 @default.
- W2055175265 cites W2023985105 @default.
- W2055175265 cites W2028697741 @default.
- W2055175265 cites W2037374883 @default.
- W2055175265 cites W2041672829 @default.
- W2055175265 cites W2043902085 @default.
- W2055175265 cites W2046356965 @default.
- W2055175265 cites W2048073154 @default.
- W2055175265 cites W2049163935 @default.
- W2055175265 cites W2050085247 @default.
- W2055175265 cites W2060910588 @default.
- W2055175265 cites W2062948694 @default.
- W2055175265 cites W2068834940 @default.
- W2055175265 cites W2069372863 @default.
- W2055175265 cites W2071483270 @default.
- W2055175265 cites W2076067786 @default.
- W2055175265 cites W2077813812 @default.
- W2055175265 cites W2080435444 @default.
- W2055175265 cites W2082828965 @default.
- W2055175265 cites W2094366129 @default.
- W2055175265 cites W2094569028 @default.
- W2055175265 cites W2095826876 @default.
- W2055175265 cites W2097995306 @default.
- W2055175265 cites W2100158834 @default.
- W2055175265 cites W2102143045 @default.
- W2055175265 cites W2105017308 @default.
- W2055175265 cites W2107346812 @default.
- W2055175265 cites W2109465910 @default.
- W2055175265 cites W2109556041 @default.
- W2055175265 cites W2116813877 @default.
- W2055175265 cites W2118503880 @default.
- W2055175265 cites W2119198740 @default.
- W2055175265 cites W2121626779 @default.
- W2055175265 cites W2132177175 @default.
- W2055175265 cites W2134638467 @default.
- W2055175265 cites W2137074525 @default.
- W2055175265 cites W2137723371 @default.
- W2055175265 cites W2143467222 @default.
- W2055175265 cites W2145308813 @default.
- W2055175265 cites W2145853100 @default.
- W2055175265 cites W2148576689 @default.
- W2055175265 cites W2148586726 @default.
- W2055175265 cites W2149244682 @default.
- W2055175265 cites W2151507811 @default.
- W2055175265 cites W2155189639 @default.
- W2055175265 cites W2156222101 @default.
- W2055175265 cites W2161550811 @default.
- W2055175265 cites W2162856391 @default.
- W2055175265 cites W2164918836 @default.
- W2055175265 cites W2166980833 @default.
- W2055175265 cites W2168931543 @default.
- W2055175265 cites W2271525454 @default.
- W2055175265 cites W2279737584 @default.
- W2055175265 cites W2280151081 @default.
- W2055175265 cites W2281727437 @default.
- W2055175265 cites W2342220081 @default.
- W2055175265 cites W2766751225 @default.
- W2055175265 cites W3080530369 @default.
- W2055175265 cites W2265899709 @default.
- W2055175265 doi "https://doi.org/10.1053/j.seminoncol.2010.09.015" @default.
- W2055175265 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21074069" @default.
- W2055175265 hasPublicationYear "2010" @default.
- W2055175265 type Work @default.
- W2055175265 sameAs 2055175265 @default.
- W2055175265 citedByCount "202" @default.
- W2055175265 countsByYear W20551752652012 @default.
- W2055175265 countsByYear W20551752652013 @default.
- W2055175265 countsByYear W20551752652014 @default.
- W2055175265 countsByYear W20551752652015 @default.
- W2055175265 countsByYear W20551752652016 @default.
- W2055175265 countsByYear W20551752652017 @default.
- W2055175265 countsByYear W20551752652018 @default.
- W2055175265 countsByYear W20551752652019 @default.
- W2055175265 countsByYear W20551752652020 @default.
- W2055175265 countsByYear W20551752652021 @default.
- W2055175265 countsByYear W20551752652022 @default.